BBlogFlow

Can keeping your phone in your pocket harm sperm health? Doctor explains what the science says - The Times of India

·5d ago
Source: The Times of India
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

Mobile phone inside pant pocketThe idea that carrying a phone in your pocket might affect fertility sounds like the kind of health scare that spreads faster than the science behind it. According to Dr. Rajeev Agarwal, Founder of Dame Health and Gynaecologist and Senior Infertility Specialist at Renew Healthcare, the honest answer is more nuanced than either the alarming headlines or dismissive skepticism suggest. Multiple meta-analyses, including one pooling 18 studies and over 4,000 semen samples, have found mobile phone radiofrequency exposure (RF-EMR) consistently associated with reduced sperm motility and viability. Interestingly, the effect on sperm concentration, the actual "count", has been far less consistent, with several studies finding no clear association at all. "This is where the headline oversimplifies things," says Dr. Agarwal. "Motility and viability show a more consistent signal than count specifically. "Some analyses found the effect more pronounced when phones are carried in front trouser pockets specifically, close to the testes.

This article is an excerpt. To read the full content, visit the original source. The Times of India

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·